Deals
Actelion Chief Pledges Caution on Drug Prices After U.S. Turmoil
- Some drugmakers `behaved badly,' dragging others in their wake
- Independence isn't a given, but Actelion hasn't gotten offers
This article is for subscribers only.
Actelion Ltd.’s Chief Executive Officer Jean-Paul Clozel pledged to be cautious when it comes to pricing the Swiss drugmaker’s new lung medicine and said he hopes the few extreme examples that captured headlines in recent weeks "will disappear."
Some drugmakers “have been behaving badly and we’re all being put in the same basket, unfortunately,” Clozel said in a telephone interview on Tuesday. “Prices have to be set very carefully."